275 related articles for article (PubMed ID: 22479444)
1. Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity.
Schulze-Topphoff U; Shetty A; Varrin-Doyer M; Molnarfi N; Sagan SA; Sobel RA; Nelson PA; Zamvil SS
PLoS One; 2012; 7(3):e33797. PubMed ID: 22479444
[TBL] [Abstract][Full Text] [Related]
2. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor.
Thöne J; Ellrichmann G; Seubert S; Peruga I; Lee DH; Conrad R; Hayardeny L; Comi G; Wiese S; Linker RA; Gold R
Am J Pathol; 2012 Jan; 180(1):267-74. PubMed ID: 22152994
[TBL] [Abstract][Full Text] [Related]
3. Modulation of MS-like disease by a multi epitope protein is mediated by induction of CD11c
Kaushansky N; Kaminitz A; Allouche-Arnon H; Ben-Nun A
J Neuroimmunol; 2019 Aug; 333():476953. PubMed ID: 31108399
[TBL] [Abstract][Full Text] [Related]
4. Laquinimod, a prototypic quinoline-3-carboxamide and aryl hydrocarbon receptor agonist, utilizes a CD155-mediated natural killer/dendritic cell interaction to suppress CNS autoimmunity.
Ott M; Avendaño-Guzmán E; Ullrich E; Dreyer C; Strauss J; Harden M; Schön M; Schön MP; Bernhardt G; Stadelmann C; Wegner C; Brück W; Nessler S
J Neuroinflammation; 2019 Feb; 16(1):49. PubMed ID: 30808363
[TBL] [Abstract][Full Text] [Related]
5. 1,25-dihydroxyvitamin D
Xie Z; Chen J; Zheng C; Wu J; Cheng Y; Zhu S; Lin C; Cao Q; Zhu J; Jin T
Immunology; 2017 Nov; 152(3):414-424. PubMed ID: 28617989
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic role of interferon-γ in experimental autoimmune encephalomyelitis is mediated through a tolerogenic subset of splenic CD11b
Arellano G; Acuña E; Loda E; Moore L; Tichauer JE; Castillo C; Vergara F; Burgos PI; Penaloza-MacMaster P; Miller SD; Naves R
J Neuroinflammation; 2024 May; 21(1):144. PubMed ID: 38822334
[TBL] [Abstract][Full Text] [Related]
7. Modulation of dendritic cell properties by laquinimod as a mechanism for modulating multiple sclerosis.
Jolivel V; Luessi F; Masri J; Kraus SH; Hubo M; Poisa-Beiro L; Klebow S; Paterka M; Yogev N; Tumani H; Furlan R; Siffrin V; Jonuleit H; Zipp F; Waisman A
Brain; 2013 Apr; 136(Pt 4):1048-66. PubMed ID: 23518712
[TBL] [Abstract][Full Text] [Related]
8. Developmental maturation of innate immune cell function correlates with susceptibility to central nervous system autoimmunity.
Hertzenberg D; Lehmann-Horn K; Kinzel S; Husterer V; Cravens PD; Kieseier BC; Hemmer B; Brück W; Zamvil SS; Stüve O; Weber MS
Eur J Immunol; 2013 Aug; 43(8):2078-88. PubMed ID: 23637087
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Interferon Regulatory Factor 4 Suppresses Th1 and Th17 Cell Differentiation and Ameliorates Experimental Autoimmune Encephalomyelitis.
Yang C; He D; Yin C; Tan J
Scand J Immunol; 2015 Oct; 82(4):345-51. PubMed ID: 26110284
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome Proliferator-Activated Receptor-δ Acts within Peripheral Myeloid Cells to Limit Th Cell Priming during Experimental Autoimmune Encephalomyelitis.
Drohomyrecky PC; Doroshenko ER; Akkermann R; Moshkova M; Yi TJ; Zhao FL; Ahn JJ; McGaha TL; Pahan K; Dunn SE
J Immunol; 2019 Nov; 203(10):2588-2601. PubMed ID: 31578267
[TBL] [Abstract][Full Text] [Related]
11. Amlexanox attenuates experimental autoimmune encephalomyelitis by inhibiting dendritic cell maturation and reprogramming effector and regulatory T cell responses.
Quan MY; Song XJ; Liu HJ; Deng XH; Hou HQ; Chen LP; Ma TZ; Han X; He XX; Jia Z; Guo L
J Neuroinflammation; 2019 Mar; 16(1):52. PubMed ID: 30823934
[TBL] [Abstract][Full Text] [Related]
12. 4-Ethylguaiacol modulates neuroinflammation and Th1/Th17 differentiation to ameliorate disease severity in experimental autoimmune encephalomyelitis.
Weng WT; Kuo PC; Brown DA; Scofield BA; Furnas D; Paraiso HC; Wang PY; Yu IC; Yen JH
J Neuroinflammation; 2021 May; 18(1):110. PubMed ID: 33975618
[TBL] [Abstract][Full Text] [Related]
13. Mannan-conjugated myelin peptides prime non-pathogenic Th1 and Th17 cells and ameliorate experimental autoimmune encephalomyelitis.
Tseveleki V; Tselios T; Kanistras I; Koutsoni O; Karamita M; Vamvakas SS; Apostolopoulos V; Dotsika E; Matsoukas J; Lassmann H; Probert L
Exp Neurol; 2015 May; 267():254-67. PubMed ID: 25447934
[TBL] [Abstract][Full Text] [Related]
14. Ingested (oral) anti-IL-12/23 inhibits EAE.
Brod SA
J Neurol Sci; 2016 Feb; 361():19-25. PubMed ID: 26810510
[TBL] [Abstract][Full Text] [Related]
15. Regulation of IL-10 and IL-17 mediated experimental autoimmune encephalomyelitis by S-nitrosoglutathione.
Singh I; Nath N; Saxena N; Singh AK; Won JS
Immunobiology; 2018 Oct; 223(10):549-554. PubMed ID: 29960806
[TBL] [Abstract][Full Text] [Related]
16. Laquinimod enhances central nervous system barrier functions.
Lühder F; Kebir H; Odoardi F; Litke T; Sonneck M; Alvarez JI; Winchenbach J; Eckert N; Hayardeny L; Sorani E; Lodygin D; Flügel A; Prat A
Neurobiol Dis; 2017 Jun; 102():60-69. PubMed ID: 28235673
[TBL] [Abstract][Full Text] [Related]
17. Presenilin1 regulates Th1 and Th17 effector responses but is not required for experimental autoimmune encephalomyelitis.
Cummings M; Arumanayagam ACS; Zhao P; Kannanganat S; Stuve O; Karandikar NJ; Eagar TN
PLoS One; 2018; 13(8):e0200752. PubMed ID: 30089166
[TBL] [Abstract][Full Text] [Related]
18. Th17 cells induce Th1-polarizing monocyte-derived dendritic cells.
Davidson MG; Alonso MN; Yuan R; Axtell RC; Kenkel JA; Suhoski MM; González JC; Steinman L; Engleman EG
J Immunol; 2013 Aug; 191(3):1175-87. PubMed ID: 23794631
[TBL] [Abstract][Full Text] [Related]
19. Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis.
Varrin-Doyer M; Zamvil SS; Schulze-Topphoff U
Exp Neurol; 2014 Dec; 262 Pt A():66-71. PubMed ID: 24731945
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy of suppressing the Jak/STAT pathway in multiple models of experimental autoimmune encephalomyelitis.
Liu Y; Holdbrooks AT; De Sarno P; Rowse AL; Yanagisawa LL; McFarland BC; Harrington LE; Raman C; Sabbaj S; Benveniste EN; Qin H
J Immunol; 2014 Jan; 192(1):59-72. PubMed ID: 24323580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
